Navitoclax
- Generic Name
- Navitoclax
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C47H55ClF3N5O6S3
- CAS Number
- 923564-51-6
- Unique Ingredient Identifier
- XKJ5VVK2WD
- Background
Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies, among others.
...
- Associated Conditions
- -
- Associated Therapies
- -
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 17
- Registration Number
- NCT01557777
- Locations
- 🇮🇱
Site Reference ID/Investigator# 77637, Rechovot, Israel
🇺🇸Site Reference ID/Investigator# 74036, La Jolla, California, United States
🇺🇸Site Reference ID/Investigator# 74033, Bethesda, Maryland, United States
A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT01423539
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT01121133
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath